Farmeco 2022;23(1)1-12.html Farmeconomia. Health economics and therapeutic pathways 2022; 23(1): 1-12 https://doi.org/10.7175/fe.v23i1.1516 Original Research Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy Patrizia Berto 1, Marco Bellone 2, Alice Sabinot 2, Carmine Pinto 3, Massimo Martino 4, Daniele Generali 4, Pier Luigi Carriero 5, Maria Domenica Sanna 1 1 Regulatory Pharma Net srl, Pisa, Italy 2 AdRes HE&OR, Turin, Italy 3 Medical Oncology Unit, Comprehensive Cancer Centre, AUSL-IRCCS,Reggio Emilia, Italy 4 Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Trieste, Italy 5 Accord Healthcare Italy Abstract INTRODUCTION: Current Italian guidelines recommend prophylaxis with granulocyte colony-stimulating factors (G-CSFs) to reduce the risk of chemotherapy-induced febrile neutropenia (FN). The availability of G-CSF biosimilars represents an opportunity for savings in the Italian National Healthcare Service (NHS) delivery of care. OBJECTIVE: To assess the cost saving potential associated with the introduction of pegfilgrastim biosimilars to local formularies, compared to the current G-CSF standard practice in Italy. METHODS: A budget impact model was developed to compare the current standard practice of long-acting (LA) and short-acting (SA) G-CSFs use, with a future scenario in which the market share of LA G-CSFs grows due to the more advantageous administration schedule and price of pegfilgrastim biosimilar. The analysis included G-CSF treatment schedules, drug acquisition costs and costs of patient management including hospitalization and ambulatory care. RESULTS: The introduction of pegfilgrastim biosimilar resulted in cumulative 3-year cost savings of € 59,650 and € 41,539 for FN prophylaxis in a potential cohort of 1000 patients with solid tumors and lymphomas, respectively. CONCLUSIONS: The results indicate that the introduction of pegfilgrastim biosimilar is potentially associated with substantial cost savings for the Italian healthcare system. Keywords Biosimilars; Budget Impact Analysis; Cost saving; Febrile neutropenia; Granulocyte colony stimulating factor (G-CSF) Corresponding author Maria Domenica Sanna m.sanna@regulatorypharmanet.com Received: 17 November 2021 Accepted: 24 January 2022 Published: 02 February 2022 Introduction Febrile neutropenia (FN) is a potentially fatal hematologic toxicity of myelosuppressive cancer chemotherapy that may lead to severe infections, sepsis, and death [1]. FN is defined as an oral temperature >38.3 °C or 2 consecutive readings of >38.0 °C for 2 h and an absolute neutrophil count (ANC) of <0.5 x 109/L [2]. The incidence of FN has been estimated to be as high as 117 cases per 1000 cancer patients [1]. FN causes a significant burden to the healthcare system, often requiring dose reductions, imposing treatment delays, and/or treatment interruptions, which can consequently reduce the efficacy of chemotherapy, resulting in worse survival outcomes and with mortality rates up to 21% [2-4]. One of the primary treatment strategies to reduce the risk of FN is the prophylactic use of granulocyte colony stimulating factor (G-CSF). G-CSF is a biological growth factor that supports the proliferation, differentiation, and activation of hematopoietic cells [5,6]. Current national and international guidelines support the use of G-CSFs as primary prophylaxis alongside chemotherapy administration, when the risk of FN is >20% [2,7,8]. Treatment with G-CSFs is associated with reduced risk of FN, shorter FN-related hospitalization, and lower mortality rate due to infection [9,10]. In addition, patients treated with G-CSFs are associated with increased probability of receiving full doses of chemotherapy [9] as well as use of highly myelosuppressive dose-dense regimens at shorter intervals than would be possible without G-CSF support [9,11]. Two types of G-CSF are available: short-acting (SA) (e.g. lenograstim and filgrastim) and long-acting (LA) (e.g. pegfilgrastim and lipegfilgrastim). SA G-CSFs are administered as a daily subcutaneous injection (for a recommended ≥10 days per cycle), while LA G-CSFs are given as a subcutaneous injection once per chemotherapy cycle [12]. Although, there are no differences in efficacy between LA G-CSF and SA G-CSF, when correctly used [7,13], LA G-CSFs are less burdensome to administer (once per cycle with long-acting vs. up to 11 injections with short-acting G-CSFs) with better compliance, and decreased burden for healthcare professionals and patients in solid tumors or non-Hodgkin’s lymphomas (NHL) [14]. In clinical practice the use of LA G-CSF improved adherence to G-CSF guidelines [15] and consequently maximized the preventive effect in terms of reduction of chemotoxic events, delays and interruptions of chemotherapy treatment. Additionally, Rosti et al., reported that the long-lasting G-CSF pegfilgrastim, represents an optimal prophylaxis strategy for FN providing, in addition to the clinical benefit for the patient, important savings to the Italian National Health Service (NHS) [16]. A reason for the low rate of G-CSF prophylaxis use, is the historically high acquisition cost of G-CSFs, causing health systems to be mindful about the potential impact on overall drug-related costs [17]. However, with the introduction of biosimilar G-CSFs, significant cost savings with the same quality of care may be achieved. In Italy, pegfilgrastim biosimilars, available since 2019, offer clinical and economic benefits in FN management [18-21]. We report the results of a budget impact model (BIM) that was developed to understand the economic impact for the Italian NHS of introducing pegylated LA G-CSFs in local formularies. Materials and Methods Model overview A budget impact model was developed in Microsoft ExcelTM to estimate the cost impact of G-CSFs from the perspective of the Italian healthcare system. The model was developed in accordance with the Principles of Good Practice for Budget Impact Analysis from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) [22]. To identify suitable references for the model, a targeted review of the relevant literature was undertaken through the PubMed/Medline database, supplemented by additional, local language and grey literature studies identified by the authors. A “current (reference) scenario” was compared with a “future (hypothetical) scenario”, in which the shares of patients (number of chemotherapy cycles) were redistributed favouring LA G-CSFs, due to the driving effect of increasing use of pegfilgrastim biosimilar. The model calculated for each year of simulation the resources consumed by a cohort of target patients treated with G-CSFs for FN prophylaxis. The costs of drug acquisition, hospitalization and outpatient management for FN were calculated for each type of G-CSF: SA and LA, to provide a per-patient cost. The per-patient costs, specific for each G-CSF, were multiplied by the number of annual patients in both the current and future scenarios over a 3-year timeframe. The difference between the two scenarios provided the budget impact (Figure 1). Figure 1. Flow of the model Target population Solid tumors Lymphomas SA G-CSF LA G-CSF SA G-CSF LA G-CSF Number of CT cycle per-patient 4.72 4.72 6.06 6.06 Days of cycle per-patient 5.09 1 5.65 1 Table I. Duration of treatment with G-CSFs CT = computer tomography; G-CSF = granulocyte colony stimulating factor; LA = long-acting; SA = short-acting The analysis evaluated the resource consumption of a cohort of patients for whom G-CSF prophylaxis was indicated, more specifically: patients with high (≥20%) FN risk and patients with intermediate (10-20%) risk of FN, with unfavourable multifactorial assessment, as recommended by AIOM Guidelines [7]. The analysis was carried out on a hypothetical cohort of 1000 patients’ population affected by either haematological tumors, in particular lymphomas (Hodgkin’s lymphoma, HL; non-Hodgkin’s lymphoma, NHL), or solid tumors. The model also returned the overall budget impact for a mixed population, with both haematological and solid tumors: the result was weighted by type of neoplasm either with a 50/50% ratio or, with a 33/67% ratio (lymphomas: 33%; solid tumors: 67%) as reported by Almenar-Cubells et al. [23], assuming this distribution may apply to the current Italian context. Drug acquisition costs The cost of therapy for SA and LA G-CSFs was calculated from the unit price and the number of doses required to complete each therapeutic cycle. The recommended dose of LA G-CSF is one vial per chemotherapy course [24] and, the daily dose of filgrastim which depends on patient’s weight is one or two vials for patients with body weight <60 Kg and ≥60 Kg, respectively [25-27]. The duration of treatment with G-CSFs per chemotherapy cycle was taken from the literature (Supplementary Tables I-IV) and the mean value is reported in Table I. The price per unit dose of each G-CSFs corresponds to the tender price negotiated between the winning manufacturer and the regional purchasing centre, as outlined in Table II. An average price was calculated for the Italian scenario, based on regional population weights. The so-called distribution on behalf of the Local Health Authority (DPC) (i.e. an additional cost, paid by the NHS for distribution via retail pharmacy stores) is determined by regional authorities and applied to every drug unit supplied; the Model is based on the assumption that all doses are supplied through retail pharmacies (DPC = 100%). At the national level, DPC cost was calculated as the average of the tariffs for each region, weighed by regional populations (Table II). Trento and Bolzano took part in the same tender as Liguria for pegfilgrastim and filgrastim. Valle d’Aosta and Molise took part in the same tender as Piemonte for pegfilgrastim. Valle d’Aosta took part in the same tender as Piemonte for filgrastim. The tender prices for lipegfilgrastim are the same for all regions. Umbria: lack of sufficient information, only the price of filgrastim and lipegfilgrastim for this region is considered. Emilia Romagna, price for pegfilgrastim set out of tender: 100 €. Region DPC (€) Price per dose unit (€) SA G-CSF LA G-CSF Filgrastim Pegfilgrastim Lipegfilgrastim Abruzzo 7.44 4.06 73.27 566.06 Basilicata 4.00 5.40 75.00 566.06 Calabria 4.60 3.94 73.00 566.06 Campania 6.00 5.23 67.85 566.06 Emilia Romagna 3.20 4.08 100.00 566.06 Friuli Venezia Giulia 6.50 3.91 71.19 566.06 Lazio 1.50 3.94 71.80 566.06 Liguria 3.90 4.18 125.00 566.06 Lombardia 7.00 4.05 75.09 566.06 Marche 3.50 5.98 91.45 566.06 Molise 5.00 6.99 73.00 566.06 Piemonte 5.00 4.44 73.00 566.06 PA Trento 6.30 4.18 125.00 566.06 PA Bolzano 5.10 4.18 125.00 566.06 Puglia 5.10 4.50 72.60 566.06 Sardegna 5.90 4.18 91.45 566.06 Sicilia 4.30 4.29 78.00 566.06 Toscana 4.68 5.70 78.00 566.06 Umbria 4.50 4.71 NA 566.06 Valle d’Aosta 7.00 4.44 73.00 566.06 Veneto 5.20 5.81 75.00 566.06 ITALY 4.93 1 4.59 2 75.80 2 566.06 Table II. Drug Regional price and DPC price 1 Average value weighted by the size of the regional population 2 Weighted average value for the expected regional annual consumption DPC = distribution on behalf of the Local Health Authority; G-CSF = granulocyte colony stimulating factor; LA = long-acting; NA = information not available; PA = autonomous province; SA = short-acting Clinical inputs Consumption of resources for management of FN, included grade 3-4 severity events (based on the Common Terminology Criteria for Adverse Events version 5—CTCAE). FN incidence rate and FN hospitalization rates specific for SA and LA G-CSF were taken from the literature (Table III). The difference between incidence of FN and incidence of hospitalization for FN was used as a proxy for FN events managed in the outpatient setting. Clinical Input (%) SA G-CSF LA G-CSF Reference Filgrastim Pegfilgrastim Lipegfilgrastim Solid tumors FN incidence 13.30 6.70 3.661 Filgrastim and pegfilgrastim:[28] Lipegfilgrastim:[29] FN hospitalization incidence 10.90 2.80 1.53 [28] FN outpatient incidence 2.40 3.90 2.13 Difference between incidence of FN and incidence of hospitalizations for FN Toxicity 5.40 1.30 1.30 [23] Lymphomas FN incidence 17.30 15.65 15.651 Filgrastim and pegfilgrastim: mean value [30] and [31] Lipegfilgrastim:[32] FN hospitalization incidence 10.71 15.65 15.65 Filgrastim and pegfilgrastim: mean value [31] and assumption2 Pegfilgrastim and lipegfilgrastim: [32] FN outpatient incidence 6.59 0.00 0.00 Difference between incidence and incidence of hospitalizations for FN Toxicity 5.40 1.30 1.30 [23] Table III. Clinical inputs for solid tumors and lymphomas 1 Based on relative risk (RR) 2 In the absence of the hospitalization data in Chan 2011, the same ratio is maintained between hospitalization for FN and the FN rate observed in Bozzoli 2015 FN = febrile neutropenia; G-CSF = granulocyte colony stimulating factor; LA = long-acting; SA = short-acting Cost per event was valued assuming the perspective of the third payer, and considering the tariffs by Diagnosis Related Group (DRG) for FN management in the hospital setting (€ 2,387.75), cost per outpatient visit (€ 20.66) and for toxicity management (€ 1,312.44) [33,34]. As to the occurrence of FN in the outpatient setting, a course of therapy with filgrastim with a standard duration of 11 days (average cost of treatment, € 197.48, and cost per outpatient visit, € 20.66), is considered [1]. Analysis G-CSF Market share (%) Solid tumors Lymphomas SA (filgrastim) 67.67 65.32 LA 32.33 34.68 Pegfilgrastim 83.00 83.00 Lipegfilgrastim 17.00 17.00 Table IV. Market share of G-CSFs G-CSF = granulocyte colony stimulating factor; LA = long-acting; SA = short-acting The budget impact was assessed by comparing the “current (reference) scenario”, in which the market share of G-CSFs follows what has been observed in recent years, with a “future (hypothetical) scenario”, in which the market share of LA G-CSF grows due to the more advantageous treatment schedule and price of biosimilars. The distribution of G-CSFs market shares in year 1 was computed by dividing the consumption of G-CSFs [35] by the product of G-CSF daily dose (from the respective SmPCs) and the average duration of chemotherapy cycle (Table IV). For the following years, a steady growth of pegfilgrastim market share was assumed due to the driving effect of biosimilar drugs, to the disadvantage of SA and lipegfilgrastim (Table V). For the future scenario, higher growth was assumed for pegfilgrastim market share, against lipegfilgrastim and filgrastim (Table VI). Table VII and VIII report the distribution of patients by treatment in the current and future scenario, calculated on market assumptions, assuming a target population of 1000 patients per cancer type. Year Annual increase of pegfilgrastim market share (%) Market share (%) SA G-CSF LA G-CSF Filgrastim Pegfilgrastim Lipegfilgrastim Solid tumors I 67.67 26.84 5.50 II 2 65.82 28.84 5.35 III 2 63.97 30.84 5.20 Lymphomas I 65.32 28.79 5.90 II 2 63.48 30.79 5.73 III 2 61.65 32.79 5.56 Table V. Annual distribution for current scenario G-CSF = granulocyte colony stimulating factor; LA = long-acting; SA = short-acting Year Annual increase of pegfilgrastim market share (%) Market share (%) SA G-CSF LA G-CSF Filgrastim Pegfilgrastim Lipegfilgrastim Solid tumors I 2 65.82 28.84 5.35 II 4 62.12 32.84 5.05 III 6 56.57 38.84 4.60 Lymphomas I 2 63.48 30.79 5.73 II 4 59.82 34.79 5.40 III 6 54.31 40.79 4.90 Table VI. Annual distribution for future scenario G-CSF = granulocyte colony stimulating factor; LA = long-acting; SA = short-acting Year Patients (n) SA G-CSF LA G-CSF Filgrastim Pegfilgrastim Lipegfilgrastim Solid tumors I 677 268 55 II 658 288 53 III 640 308 52 Lymphomas I 653 288 59 II 635 308 57 III 617 328 56 Table VII. Patients by treatment in the current scenario G-CSF = granulocyte colony stimulating factor; LA = long-acting; SA = short-acting Year Patients (n) SA G-CSF LA G-CSF Filgrastim Pegfilgrastim Lipegfilgrastim Solid tumors I 658 288 53 II 621 328 50 III 566 388 46 Lymphomas I 635 308 57 II 598 348 54 III 543 408 49 Table VIII. Patients by treatment in the future scenario G-CSF = granulocyte colony stimulating factor; LA = long-acting; SA = short-acting Results The results of the budget impact were calculated as the difference between current and future scenario costs. The introduction of pegfilgrastim biosimilars in the treatment of FN results in substantial cost savings, with different biosimilar penetration over 3 years. The budget impact analysis estimated that by introducing LA G-CSFs in particular pegfilgrastim biosimilars, in place of SA G-CSF treatments, € 59,650 could be saved over 3 years (€ 8,521 in year 1, € 17,043 in year 2, € 34,086 in year 3) for every 1000 patients affected by solid tumors and treated with G-CSFs (Table IX). The reduction of consumption of SA in favour of LA G-CSFs would result in total cost savings of € 5,934 in year 1, € 11,868 in year 2, € 23,737 in year 3, leading to a cumulative 3-year cost savings of € 41,539 for every 1000 patients affected by lymphomas and treated with G-CSFs (Table X). Year SA G-CSF LA G-CSF Budget impact – future vs. current scenario (€) Filgrastim (€) Pegfilgrastim (€) Lipegfilgrastim (€) I -14,160 10,179 -4,540 -8,521 II -28,320 20,358 -9,081 -17,043 III -56,640 40,716 -18,162 -34,086 Cumulative -99,120 71,253 -31,783 -59,650 Table IX. Budget Impact – Solid tumors G-CSF = granulocyte colony stimulating factor; LA = long-acting; SA = short-acting Year SA G-CSF LA G-CSF Budget impact – future vs. current scenario (€) Filgrastim (€) Pegfilgrastim (€) Lipegfilgrastim (€) I -17,499 18,511 -6,945 -5,934 II -34,999 37,021 -13,891 -11,868 III -69,998 74,043 -27,782 -23,737 Cumulative -122,496 129,575 -48,618 -41,539 Table X. Budget Impact – Lymphomas G-CSF = granulocyte colony stimulating factor; LA = long-acting; SA = short-acting Figure 2 and Figure 3 show the annual budget impact compared with the expenditure for pegfilgrastim in patients affected by solid tumors and lymphomas, respectively. Indeed, this budget impact model shows that increasing the NHS’ expenditure for pegfilgrastim biosimilars over 3-years, would increase savings for the Italian NHS. Figure 2. Budget Impact over 3 years – Solid tumor Figure 3. Budget Impact over 3 years – Lymphomas Table XI shows the results of the budget impact analysis on a patient population affected by both solid and haematological tumors: the expected savings are approximately € 50,000 for every 1000 patients treated, considering a population distribution from the literature [23]. Year SA G-CSF LA G-CSF Budget impact – future vs. current scenario (€) Filgrastim (€) Pegfilgrastim (€) Lipegfilgrastim (€) I -15,262 12,928 -5,334 -7,668 II -30,524 25,857 -10,668 -15,335 III -61,048 51,714 -21,336 -30,671 Cumulative -106,834 90,499 -37,339 -53,674 Table XI. Budget Impact – All tumors G-CSF = granulocyte colony stimulating factor; LA = long-acting; SA = short-acting Discussion The recent patent expiration of several biological drugs led to the commercialisation of biosimilar products, nowadays representing an important segment of the global pharmaceutical market. Biosimilar penetration has been observed across the five major European Union (EU) markets and Italy has registered a high and increasing biosimilars up-take, albeit not uniform across the Italian regions [36,37]. The recent licensing in Europe of biosimilar pegfilgrastim-containing products offers the opportunity to deliver the additional advantages of long-over short-acting G-CSF at a reduced cost. For countries currently using reference pegfilgrastim, evident cost savings are reported by switching to biosimilar pegfilgrastim [18,20,21]. In the past 10 years, the introduction of SA G-CSF biosimilars favoured their adoption due to their cost-efficiency in reducing the incidence of FN in chemotherapy-treated patients than SA G-CSF originator and LA G-CSFs [38,39]; hence, a similar pattern is expected for the LA G-CSFs category. These results are consistent with our findings which showed that the introduction of pegfilgrastim biosimilars in place of SA G-CSF treatments, have a substantial cost-saving potential for the Italian NHS. The budget impact was sensitive to pegfilgrastim biosimilar market uptake rate and greater savings are observed whenever the expenditure for pegfilgrastim biosimilar is higher. The analysis highlighted the economic advantage of using pegfilgrastim biosimilars in place of SA G-CSF treatments in the FN treatment setting, providing a substantial cumulative cost saving of € 59,650 and € 41,539 respectively for a 1000 patients’ population with solid tumors and lymphomas over a 3-years’ timeframe. A confirmation of our analysis comes from the results of a budget impact model built by Ravasio et al. [21] in order to assess the economic impact generated in Italy from the use of the pegfilgrastim biosimilar compared to the originator. These authors showed that the availability of the biosimilar could (in five years) generate cumulated savings as high as € 6.4 million for the whole Italian NHS [21]. However, this analysis did not calculate the potential savings of the introduction of pegfilgrastim biosimilar to the local formulary, compared to SA and LA G-CSFs currently used for FN prophylaxis. Additionally, the budget impact built by Ravasio et al. did not consider the effect that any regional or local tenders could exercise on the price of biosimilar and originator pegfilgrastim and costs of patient management including hospitalization and ambulatory care. Our findings are in line with the cost savings observed across EU markets and the US switching from the reference product to pegfilgrastim biosimilar [18-20]. Tilleul et al. revealed that extending pegfilgrastim biosimilar to patients on both LA G-CSF and SA G-CSF could provide substantial mean cost savings to the French healthcare system over 5 years [20]. A meta-analysis found that in randomized clinical trials (RCTs), there was no statistically significant difference in the incidence of FN and FN-related complications between short and long-acting G-CSFs, whereas in non-RCTs, the overall risk of FN was lower within long-acting G-CSF than with short-acting G-CSF [12]. Mitchell et al. conducted a review of comparative effectiveness of long vs. short-acting G-CSFs in real-world clinical settings and also found that risks of FN and FN-related complications were generally lower for prophylaxis with pegfilgrastim versus prophylaxis with short acting G-CSFs, which might be attributed to under-dosing of short-acting G-CSFs per chemo-cycle in routine clinical practice [13]. The opportunity to switch more patients to LA G-CSF may have the potential to improve patient outcomes [37,40,41]. No requirement for daily self-administration, hospital visits, or regular tests to evaluate absolute neutrophil count levels, may also provide improved compliance with LA over SA G-CSF [42,43], thus reducing indirect costs, such as patients’ and caregivers’ time and costs, as well as productivity losses or reductions. Worth mentioning is that the current clinical practice for SA G-CSFs does not observe the recommended posology of at least 11 days of administration per cycle, essential to achieve comparable efficacy to LA G-CSFs [1], but rather falls within the 4 to 6 range [44-46]. The main determinant in favour of a switch to LA G-CSFs, when feasible, is, thus, their facilitated administration management—especially in the instance of FN or adverse events occurrence—as therapeutic continuity can be assured, nevertheless. Furthermore, the introduction of auto-injection devices, which allows to automatically insert the needle and deliver a controlled dose of drug, has demonstrated that it may increase treatment adherence and, consequently, reduce costs by decreasing the frequency of hospital visits [47]. Overall, the auto-injection improves the injection experience by mitigating fear and anxiety, overcomes the challenges resulting from hand dexterity problems, and empowers patients to take control of their treatment journey [48]. In a recent publication, the HCPs identified multiple major HCP benefits in administering subcutaneous injections via auto-injector including ease of use, fewer needle-stick injuries, more consistent dosing, and faster administration. HCPs also thought that use of an autoinjector would provide major benefits to patients facilitating therapeutic adherence [48]. Additionally, the introduction of auto-injectors as an alternative route of administration for pegfilgrastim biosimilar could improve the quality of life of oncology patients, increasing patient self-efficacy, feelings of independence, adherence to medications and, ultimately, saving healthcare and social costs [49-51]. Therefore, the potential cost savings due to the introduction and increased use of pegfilgrastim biosimilars could improve potential advantages of LA G-CSFs treatment, increasing rate of G-CSF prophylaxis and leading to clinical improvements in key areas such as FN hospitalization, chemotherapy delivery and response rates. Although the results of this budget impact model further highlight the relevance of biosimilar uptake in clinical practice to reduce total costs, some limitations of this study are associated with the economic model itself. This model represents a simplification of the complex utilization patterns of G-CSF prophylaxis within a hypothetical oncology practice population plan. In fact, the generalizability of the model results is limited to clinical input assumptions and distribution of patients based on published literature data. In conclusion, our study demonstrates that the introduction and increased use of pegfilgrastim biosimilars has the potential to reduce healthcare costs in Italy for prophylaxis of FN among patients with cancer who are undergoing myelosuppressive chemotherapy. Pegfilgrastim biosimilars offer a fresh opportunity to rethink neutropenia management and value of G-CSF, based on the significant potential for both clinical and economic benefits, thus providing to payers, physicians and patients a life-saving strategy. Funding This study and manuscript writing were funded by Accord Healthcare Italia Srl. Conflicts of interest PB and MDS are consultants of Regulatory Pharma Net srl. MB and AS are employees of AdRes. DG reports Honoraria from Novartis, Roche and Lilly, Research Funding from Novartis, LILT and Astra-Zeneca, outside of the submitted work. CP reports personal fees for advisory role, speaker engagements and travel and accommodation expenses from Amgen, Astellas, AstraZeneca, Bayer, Bristol Meyer Squibb, Celgene, Clovis Oncology, Eisai, Ipsen, Janssen, Incyte, Merck-Serono, Merck Sharp and Dohme, Novartis, Roche, Sandoz, Sanofi, and Servier, outside the submitted work. MM declares Honoraria from Novartis, Kite/Gilead, BMS, MSD, JAZZ, Jansenn, Tillomed, outside of the submitted work. PLC acts as Medical Consultant for Accord Healthcare Italy References 1. Aapro M, Boccia R, Leonard R, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer 2017;25:3295-304; https://doi.org/10.1016/s0959-8049(17)30619-6 2. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 2016;27:111-8; https://doi.org/10.1093/annonc/mdw325 3. Wang L, Baser O, Kutikova L, et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and Meta-analysis of randomized controlled trials. Support Care Cancer 2015;23:3131-3140; https://doi.org/10.1007/s00520-015-2686-9 4. Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008;16:1299-1309; https://doi.org/10.1007/s00520-008-0430-4 5. Bennett CL, Djulbegovic B, Norris LB, et al. Colony-stimulating factors for febrile neutropenia during cancer therapy. New Engl J Med 2013;368:1131-39; https://doi.org/10.1056/NEJMct1210890 6. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32; https://doi.org/10.1016/j.ejca.2010.10.013 7. LG AIOM, Gestione della tossicità ematopoietica in oncologia, Edizione 2019. 8. Crawford J, Armitage J, Balducci L, et al. Myeloid growth factors. J Natl Compr Canc Netw 2013;11:1266-90; https://doi.org/10.6004/jnccn.2013.0148 9. Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013;24:2475-84; https://doi.org/10.1093/annonc/mdt226 10. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67; https://doi.org/10.1200/JCO.2006.08.8823 11. Lyman GH, Barron RL, Natoli JL, et al. Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. Crit Rev Oncol Hematol 2012;81:296-308; https://doi.org/10.1016/j.critrevonc.2011.04.010 12. Cornes P, Gascon P, Chan S, et al. Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther 2018;35:1816-29; https://doi.org/10.1007/s12325-018-0798-6 13. Mitchell S, Li X, Woods M, et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract 2016;22:702-716; https://doi.org/10.1177/1078155215625459 14. Botteri E, Krendyukov A, Curigliano G. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: a meta-analysis of randomised clinical trials in breast cancer patients. Eur J Cancer 2018;89:49-55; https://doi.org/10.1016/j.ejca.2017.10.034 15. Fagnani D, Isa L, Verga MF, et al. Granulocyte colony-stimulating factors used in clinical practice: PoloNord registry-based cohort Italian study. Tumori 2014;100:491-498; https://doi.org/10.1700/1660.18158 16. Rosti G, Lebboroni M, Cerchiari A, et al. Analisi di budget impact sull’utilizzo di pegfilgrastim nella profilassi della neutropenia febbrile in Italia. Farmeconomia e percorsi terapeutici 2011;12:119-127 17. Trotta F, Mayer F, Mecozzi A, et al. Impact of guidance on the prescription patterns of G-CSFs for the prevention of febrile neutropenia following anticancer chemotherapy: A population-based utilization study in the Lazio region. BioDrugs 2017;31:117-124; https://doi.org/10.1007/s40259-017-0214-9 18. Cornes P, Gascon P, Vulto AG, et al. Biosimilar Pegflgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure. BioDrugs 2020;34:255-263; https://doi.org/10.1007/s40259-020-00411-4 19. Wang W, Li E, Campbell K, et al. Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients with Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework. JCO Oncology Practice 2021;17:1139-1149; https://doi.org/10.1200/OP.20.00994 20. Tilleul PR, Rodgers-Gray BS, Edwards JO. Introduction of biosimilar pegfilgrastim in France: Economic analysis of switching from originator. J Oncol Pharm Practice 2020;0:1-12; https://doi.org/10.1177/1078155220962208 21. Ravasio R, Antonuzzo L, Danova, et al. Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy. AboutOpen 2020;7:04-08; https://doi.org/10.33393/abtpn.2020.2030 22. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17:5-14; https://doi.org/10.1016/j.jval.2013.08.2291 23. Almenar-Cubells D, Mayans J, Juan O, et al. Pegfilgrastim and daily granulocyte colony-stimulating Factor: Patterns of use and Neutropenia-related outcomes in cancer patients in Spain-results of the LEARN study. Eur J Cancer Care (Engl) 2009;18:280-286; https://doi.org/10.1111/j.1365-2354.2008.00959.x 24. PELGRAZ Summary of Product Characteristics. Available at https://www.ema.europa.eu/en/documents/product-information/pelgraz-epar-product-information_en.pdf (last accessed October 2018) 25. Green M, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35; https://doi.org/10.1093/annonc/mdg019 26. Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 2003;44:1503-1508; https://doi.org/10.1080/1042819031000103953 27. Romieu G, Clemens M, Mahlberg R, et al. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high-risk breast cancer: A randomized Phase 2 trial. Crit Rev Oncol Hematol 2007;64:64-72; https://doi.org/10.1016/j.critrevonc.2006.12.007 28. Almenar Cubells D, Bosch Roig C, Jiménez Orozco E, et al. Effectiveness of daily versus non‐daily granulocyte colony‐stimulating factors in patients with solid tumours undergoing chemotherapy: A multivariate analysis of data from current practice. Eur J Cancer Care (Engl) 2013;22:400-412; https://doi.org/10.1111/ecc.12043 29. Bondarenko I, Gladkov OA, Elsaesser R, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC cancer 2013;13:386; https://doi.org/10.1186/1471-2407-13-386 30. Chan A, Leng XZ, Chiang JY, et al. Comparison Of Daily Filgrastim And Pegfilgrastim To Prevent Febrile Neutropenia In Asian Lymphoma Patients. Asia Pac J Clin Oncol 2010;7:75-81; https://doi.org/10.1111/J.1743-7563.2010.01355.X 31. Bozzoli V, Tisi MC, Maiolo E, et al. Four doses of Unpegylated versus one dose of pegylated Filgrastim as supportive therapy IN R-CHOP-14 for elderly patients with Diffuse Large B-cell lymphoma. Br J Haematol 2015;169:787-794; https://doi.org/10.1111/bjh.13358 32. Link H, Illerhaus G, Martens UM, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Support Care Cancer 2021;29:2519-2527; https://doi.org/10.1007/s00520-020-05711-7 33. Lazzaro C, Bordonaro R, Cognetti F, et al. An Italian cost-effectiveness analysis OF paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: The COSTANza study. Clinicoecon Outcomes Res 2013;5:125–135; https://doi.org/10.2147/ceor.s41850 34. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza postacuzie e di assistenza specialistica ambulatoriale. Decreto 10/2012 e pubblicato in GU Serie Generale n.23 del 28-1-2013 35. IMS Data. IMS MAT data on G-CSF up to September 2020. 36. Farmaci Biologici E Biosimilari. Scenari terapeutici e stima del risparmio per il Sistema Sanitario italiano. Centro Studi IQVIA Italia. Available at https://assobiotec.federchimica.it/docs/default-source/default-document-library/(iqvia)_farmaci_biologici_e_biosimilari.pdf?sfvrsn=853ad623_0 (Last accessed March 2019) 37. Guidotti E, Vinci B, Attanasio F, et al. Effective tools to manage biosimilars prescription: The Italian experience. Health Policy and Technology 2021;10:45-51; https://doi:org/10.1016/j.hlpt.2020.10.011 38. Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract 2012;18:171-179. https://doi.org/10.1177/1078155211407367 39. Sun D, Andayani TM, Altyar A, et al. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study. Clin Ther 2015;37:842-857. https://doi.org/10.1016/j.clinthera.2015.01.011 40. Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a metaanalysis of randomized controlled trials. Curr Med Res Opin 2007;23:2283-2295; https://doi.org/10.1185/030079907X219599 41. Bond TC, Szabo E, Gabriel S, et al. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract 2018;24:412-423; https://doi.org/10.1177/1078155217714859 42. Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 2003;13:259-264; https://doi.org/10.1097/00001813-200304000-00002 43. Lambertini M, Ferreira AR, Del Mastro L, et al. Pegfilgrastim for the prevention of chemotherapy induced febrile neutropenia in patients with solid tumours. Expert Opin Biol Ther 2015;15:1799-1817; https://doi.org/10.1517/14712598.2015.1101063 44. Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006;40:402-7; https://doi.org/10.1345/aph.1G516 45. Gascón P, Aapro M, Ludwig H, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study) Support Care Cancer 2016;24:911-925; https://doi.org/10.1007/s00520-015-2861-z 46. Aapro M, Ludwig H, Bokemeyer C, et al. Predictive modeling of the outcomes of chemotherapyinduced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann Oncol 2016;27:2039-2045; https://doi.org/10.1093/annonc/mdw309 47. Tornero Molina J, Lopéz Robledillo JC, Ruiz NC. Potential Benefits of the Self Administration of Subcutaneous Methotrexate with Autoinjector Devices for Patients: A Review. Drug Healthc Patient Saf 2021;13:81-94; https://doi.org/10.2147/DHPS.S290771 48. Gandell D. Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18-45 years old. Patient Prefer Adherence 2019;13:351-61; https://doi.org/10.2147/PPA.S187120 49. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2016;38,167-71; https://doi:10.1097/01376517-200606000-00005 50. Fraser C, Morgante L, Hadjimichael O, et al. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs 2004;36:120-129; https://doi.org/10.1097/01376517-200406000-00002 51. Bayas A. Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv 2013;10:285-287; https://doi.org/10.1517/17425247.2013.763793